financetom
Business
financetom
/
Business
/
Capri Holdings Q4: Earnings Miss, Margins Squeeze Amid Sales Slump And Tariff Uncertainty
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Capri Holdings Q4: Earnings Miss, Margins Squeeze Amid Sales Slump And Tariff Uncertainty
May 28, 2025 6:26 AM

Capri Holdings Limited ( CPRI ) shares are trading lower on Wednesday after reporting fourth-quarter adjusted earnings per share of $4.90 loss, missing the Street view of 14 cents loss.

Quarterly sales of $1.035 billion (down 15.4% year over year) outpaced the analyst consensus estimate of $986.57 million. On a constant currency basis, total revenue decreased 14.1%.

Gross profit was $631 million, down from $767 million a year earlier. Gross margin declined to 61.0% from 62.7% in the prior year.

Also Read: Deal Dispatch: Harley-Davidson To Wipe Out? Plus, Prada’s Versace Purchase Garners A Fashionable Price

Adjusted loss from operations totaled $33 million, compared to adjusted operating income of $78 million in the prior year. Adjusted operating margin declined to (3.2)% from 6.4% a year ago.

“While there is uncertainty around the impact of tariffs on the global economic environment, we remain focused on executing against our new strategic initiatives that are designed to return Capri Holdings ( CPRI ) to future growth,” said chief executive officer John D. Idol.

Michael Kors reported revenue of $694 million, reflecting a 15.6% decline on a reported basis and a 14.4% fall on a constant currency basis.

Jimmy Choo generated revenue of $133 million, down 2.9% on a reported basis and 1.5% on a constant currency basis.

“We are confident in our ability to grow Michael Kors to $4 billion in revenue and Jimmy Choo to $800 million over time while restoring operating margin to the double-digit range,” Idol added.

Versace revenue of $208 million decreased 21.2% on a reported basis and 19.7% on a constant currency basis.

On April 10, Capri Holdings ( CPRI ) said it would sell Versace to Prada for $1.375 billion in cash. The deal is expected to close in the second half of 2025. Starting in fiscal 2026, Versace will be reported as a discontinued operation.

“This transaction positions us to invest in our future growth, substantially reduce our debt levels and reinstate a share repurchase program in the future,” Idol said.

The company’s quarterly results include a non-cash tax valuation allowance of $545 million taken against the company’s deferred tax assets, of which $119 million was related to Versace.

Capri Holdings ( CPRI ) exited the quarter with cash and equivalents worth $166 million and net inventories worth $869 million.

The company’s long-term debt expanded to $1.476 billion at the end of the quarter under review, up from $1.261 billion a year ago.

Outlook: Capri Holdings ( CPRI ) expects adjusted EPS for fiscal 2026 to range between $1.20 and $1.40, above the $1.06 analyst estimate.

The company lowered its fiscal 2026 sales guidance to $3.30 billion–$3.40 billion, down from a prior outlook of $4.10 billion and below the $4.11 billion consensus.

For the first quarter, the company sees total revenue of approximately $765 million to $780 million versus the $959.91 million estimate.

The firm projects earnings per share of approximately $0.10 to $0.15 versus the $0.10 estimate.

PriceAction: CPRI shares are trading lower by 4.56% to $16.75 premarket at last check Wednesday.

Read Next:

Ralph Lauren Delivers Q4 Beat Against Elevated Expectations; These Analysts Hike Price Target

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Biogen, Eisai Submit Biologics License Application for Alzheimer's Subcutaneous Autoinjector to US FDA
Biogen, Eisai Submit Biologics License Application for Alzheimer's Subcutaneous Autoinjector to US FDA
Nov 3, 2024
08:13 AM EDT, 11/01/2024 (MT Newswires) -- Biogen (BIIB) and Eisai said late Thursday that Eisai finalized a biologics license application rolling submission to the FDA for a subcutaneous autoinjector of LEQEMBI, or lecanemab-irmb, for weekly dosing in early-stage Alzheimer's disease. The device, which is designed for home or clinic use, allows a 15-second injection and supports sustained drug levels...
Cboe beats third-quarter profit estimates on strong hedging activity
Cboe beats third-quarter profit estimates on strong hedging activity
Nov 3, 2024
Nov 1 (Reuters) - Cboe Global Markets ( CBOE ) beat estimates for third-quarter profit on Friday, helped by strong options trading as investors actively hedged against geopolitical and economic uncertainties. A robust equities market, shifts in the U.S. Federal Reserve's key policy rates and the potential economic fallout from the Middle East conflict have investors and portfolio managers on...
Cardinal Health lifts annual profit outlook on strength in specialty medicines unit
Cardinal Health lifts annual profit outlook on strength in specialty medicines unit
Nov 3, 2024
Nov 1 (Reuters) - Cardinal Health ( CAH ) raised its 2025 adjusted profit forecast on Friday as strong demand for costly specialty medicines and branded drugs drove sales at its pharmaceuticals unit, sending the shares of the company up nearly 4% in premarket trading. Drug distributors have been trying to diversify their operations and gain better footing in the...
--Dominion Energy Keeps Quarterly Dividend at $0.6675 per Share, Payable Dec. 20 to Holders of Record Nov. 29
--Dominion Energy Keeps Quarterly Dividend at $0.6675 per Share, Payable Dec. 20 to Holders of Record Nov. 29
Nov 3, 2024
03:17 PM EDT, 10/31/2024 (MT Newswires) -- Price: 59.73, Change: +1.28, Percent Change: +2.18 ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved